Rezolute's Congenital HI Trial Misses Endpoint, Tumor HI Data Bolsters Confidence
Event summary
- Rezolute's Phase 3 sunRIZE study for congenital hyperinsulinism (HI) failed to meet primary or key secondary endpoints, despite demonstrating pharmacologic activity and reductions in hypoglycemia events.
- Data from Rezolute's Expanded Access Program (EAP) for tumor HI showed substantial improvement in hypoglycemia, leading to reduced dextrose/TPN dependency in 75% of patients.
- Rezolute plans to meet with the FDA in Q1 2026 to discuss the sunRIZE data and potential pathways forward.
- The upLIFT study for tumor HI, using GIR as a primary endpoint, is anticipated to release topline results in the second half of 2026.
- All 59 sunRIZE participants elected to continue treatment in an open-label extension (OLE), with some children now receiving ersodetug as monotherapy.
The big picture
Rezolute's situation highlights the challenges inherent in rare disease drug development, particularly when dealing with complex physiological processes like glucose regulation. The company's reliance on EAP data to bolster confidence in ersodetug's efficacy underscores the need for innovative trial designs and endpoints to overcome limitations in traditional clinical trials. The ongoing discussions with the FDA will be pivotal in determining the future of Rezolute's congenital HI program and its overall valuation.
What we're watching
- Regulatory Dynamics
- The FDA's response to Rezolute's data and proposed path forward for congenital HI will be critical, particularly given the missed primary endpoint and the need to characterize the study's limitations.
- Clinical Efficacy
- The ongoing open-label extension (OLE) study's results will be closely watched to determine if continued treatment translates to sustained clinical benefit and whether monotherapy use expands.
- Trial Execution
- The success of the upLIFT study, with its stringent GIR endpoint, will hinge on patient selection and the ability to mitigate the challenges observed with the placebo response in the sunRIZE trial.
Related topics